Thyrocare Technologies Limited (NSE:THYROCARE)
India
· Delayed Price · Currency is INR | Market Cap | 36.05B |
| Revenue (ttm) | 6.54B |
| Net Income (ttm) | 877.40M |
| Shares Out | n/a |
| EPS (ttm) | 16.45 |
| PE Ratio | 41.08 |
| Forward PE | n/a |
| Dividend | 18.00 (2.66%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 53,458 |
| Average Volume | 41,134 |
| Open | 682.70 |
| Previous Close | 679.65 |
| Day's Range | 680.25 - 725.60 |
| 52-Week Range | 571.40 - 1,055.00 |
| Beta | 0.46 |
| RSI | 36.43 |
| Earnings Date | May 15, 2025 |
About Thyrocare Technologies
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include profiles of tests adm... [Read more]
Financial Performance
In 2023, Thyrocare Technologies's revenue was 5.72 billion, an increase of 8.58% compared to the previous year's 5.27 billion. Earnings were 707.60 million, an increase of 9.72%.
Financial StatementsNews
Thyrocare Technologies Q3 FY25 Results: Revenue jumps 23.2% YoY to Rs 165.9 crore, Net Profit surges 24% YoY
Thyrocare Technologies has delivered a strong performance in the third quarter of FY25, reporting notable growth across key financial metrics. The company’s net profit surged by 24% year-on-year (YoY)...